Download giving purpose gaining hope - Sunnybrook Health Sciences Centre

C A N C E R
R E S E A R C H
A N D
I N N O V A T I O N
R E P O R T
2 0 0 9
giving purpose
gaining hope
giving purpose
gaining hope
C A N C E R
R E S E A R C H
A N D
I N N O V A T I O N
R E P O R T
2 0 0 9
Patients are at the
.....................
At the centre of our
cancer research & innovation:
our patients.
centre of why we
.....................
research and discover.
.....................
Patients are at the
.....................
heart of how we
.....................
translate discoveries
.....................
to deliver even better
.....................
At the heart of our
cancer research & innovation:
our donors and our staff.
models of care through
.....................
new treatments.
From the Senior Leadership, Sunnybrook Health Sciences Centre
The Odette Cancer Centre in collaboration
with the Sunnybrook Research Institute
conducts outstanding research with a
goal to translate new knowledge into the
clinic. For example, Odette Cancer Centre
researchers are leading work in chronotherapy or specially-timed chemotherapy
and radiation therapy to optimize therapeutic
activity and minimize side effects in the
treatment of several types of cancer. For
earlier interventions in prostate cancer, our
researchers have validated a calculator
.....................................................................................
Sunnybrook’s Odette Cancer Centre is a
key contributor to achieving the Hospital’s
vision to invent the future of healthcare.
We are proud of our Cancer Program
teams who provide compassionate care,
conduct leading-edge research and
educate the professionals of tomorrow. As
you will see in the pages of this report,
their work is having a profound impact on
the fight against cancer across Ontario,
throughout Canada and around the globe.
From the Vice-President, Research,
tool using all known risk factors to better
predict prostate cancer risk and the risk for
aggressive disease.
Our researchers are working with patients
with locally advanced breast cancer,
recurrent breast cancer, and prostate
cancer to use low-frequency ultrasound for
faster tracking of therapy response, to
better tailor treatments early on. Sunnybrook
is also the only Canadian site in a multicentre trial of digital tomosynthesis, a new
imaging technology drawing on the
strengths of digital mammography, and
which delivers three-dimensional images
with the potential to further improve breast
cancer detection.
These examples and many more, of our
quest for new approaches to improve
cancer care would not be possible without
our funding and healthcare partners.
For their vital and ongoing support, we
thank the community and our many partners
such as the University of Toronto, Cancer
Care Ontario, the Ministry of Health and
Long-Term Care and others in the provincial
and federal governments.
To our Odette Cancer Centre: through your
compassionate patient care and enduring
commitment to improved quality of life, thank
you for being there when it matters most.
David A. Leslie
Chair, Board of Directors
Barry A. McLellan
President and CEO
Sunnyb
device
earlier,
to trea
invasiv
new d
enhanc
Cancer research is working. Recent numbers
from the National Cancer Institute show that
fewer people are being diagnosed with
cancer or dying from it. This decrease is a
testament to the power of research to
transform clinical care.
At Sunnybrook, we are privileged to have
some of the world’s best cancer researchers,
who work in partnership across the Odette
Cancer Program, Sunnybrook Research
Institute (SRI), Cancer Care Ontario, the
Institute for Clinical Evaluative Sciences
and the University of Toronto. These scientists and clinician-scientists are, as the
numbers show, transforming patient care.
Their work spans the spectrum of discovery
from basic science to clinical impact. It
includes work to understand the mechanisms underlying the origin and growth of
tumours; and studies aimed at reconstituting
the immune systems of people devastated
by life-saving chemotherapy and radiotherapy. It includes building new imaging
Hospit
enable
and c
proxim
at the
ensure
transla
model
Also c
ships w
thanks
researc
lower m
inspirin
Our vi
care, a
Dr. Mich
Vice Pre
Researc
brook Health Sciences Centre
From the Chief, Sunnybrook’s Odette Cancer Centre, and the Program
Research Director, Cancer, Sunnybrook Health Sciences Centre
tal-based research enterprises like SRI
e interactions among our researchers
clinicians and their teams. It is this
mity that underpins our success. Being
frontline maximizes collaboration and
es that results from research are
ated quickly into new and better
ls of care.
central to our success are our partnerwith all of you in the community. It is
s to you that we can say that cancer
ch is working. And while this news of
mortality and incidence is welcome and
ng, it does not mean that we can rest.
ision is to invent the future of cancer
and we will not pause until we achieve it.
hael Julius
esident,
ch
Patients are at the centre of why we
research and discover, and the promise of
benefits to patients is why Sunnybrook’s
Odette Cancer Centre continually strives
to lead in translational cancer research.
Our annual report of research and innovation features some of the many success
stories of ‘purpose’ and ‘hope’ unfolding
everyday across our Cancer Program, and
in collaboration with Sunnybrook Research
Institute and other research partners.
These stories highlight the passion and
priority of our researchers to translate new
knowledge into clinical care, and the
measured but significant triumphs from
these efforts as reflected in the heartwarming and hopeful words of our patients.
Sunnybrook’s Odette Cancer Centre leads
as one of the largest comprehensive
cancer centres in North America. Here at
home at the provincial level, our teams
..................................................................................
es to detect and diagnose cancer
r, and building innovative technology
at cancer more precisely and less
vely. It includes leading trials to assess
devices and targeted therapies, and to
ce existing therapies and palliative care.
were recognized for leading work in innovations in cancer care delivery, and community
outreach, and garnered an unprecedented
three Quality and Innovation Awards from the
Cancer Quality Council of Ontario, Cancer
Care Ontario and the Canadian Cancer Society.
Success would not be possible without the
dedication of our staff, whose expertise,
compassion and teamwork ensure continued
quality of care for our patients.
Also critical to our success is the support
of the Board of Directors and the Senior
Leadership Team of Sunnybrook Health
Sciences Centre, and strong foundational
partnerships with the University of Toronto,
Cancer Care Ontario, and the Institute for
Clinical Evaluative Sciences.
To our donors and funding partners -- your
tremendous generosity continues to foster
new knowledge and support positive clinical
impact: thank you.
Dr. Linda Rabeneck
Chief, Odette Cancer Centre
Vice President,
Regional Cancer Services
Regional Vice President,
Cancer Care Ontario
Dr. Richard Wells
Program Research Director,
Cancer
.......................................................................................................................
Ta b l e O f C o n t e n t s
....................................................................................A
. .C. K. N
. .O. W
. .L. E. D
. .G. E. M
. .E. N
. .T.S. . . . . . . . . . . . . .
4
7
8
10
12
14
16
18
19
Messages from Senior Leadership, Sunnybrook
Health Sciences Centre
Vice President, Research, Sunnybrook
Chief, Sunnybrook’s Odette Cancer Centre,
and Program Research Director, Cancer, Sunnybrook
Research to Transform Cancer Care
Study Aims To Understand Optimal Surgical
Treatments for Younger Women With Breast Cancer
Targeted, High Intensity Treatments Show
Promise in Prostate Cancer
Long-term, Low-dose ‘Metronomic’ Anti-cancer
Chemotherapy for Effective Cancer Control
Caring for the Whole Patient: Body, Mind
and Spirit Affects Outcome
Head and Neck Cancer: Using PET Scans to
Monitor Treatment Effect
Major Sources of External Funding 2007-08
Innovation in Models of Care Delivery
20 Technological Solution Enhances Multidisciplinary
Cancer Care
22 Proportion of Total External Funding 2007-08
23 Initiatives
24 The Ongoing Support Of Funding Partners Is Vital To
Continued Advancements In Cancer Research And
Tailored Treatments
25 Odette Cancer Centre Helps Lead Improvements
In Cancer Care In Ontario
26 2008 Awards Highlights
27 Philanthropy: Thank You
31 Success: Publication Highlights
32 A Partial Summary of Full Publications from
July 2007 to June 2008
38 Rankings of Comprehensive Cancer Centres
in North America
Sunnybrook’s Odette Cancer Centre
Cancer Research and Innovation
Report 2009
Special thanks to our patients who
shared their stories for this report.
..............................
Project Support: Natalie Chung-Sayers
Writers: Natalie Chung-Sayers,
Megan Easton, Gillian Wansbrough
Photography: MediaSource
Printing: TI Group
Art Direction and Design: Say-Design
..............................
Comments/feedback:
[email protected]
..............................
Odette Cancer Centre would like to
acknowledge the support of
Communications and Stakeholder
Relations, Sunnybrook.
..............................
©2009 Sunnybrook Health Sciences Centre
..
.. .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Research
At The Centre
of Our Cancer
.....................
Research and
........................................................................................................ .....................
R
E
S
E
A
R
C
H
T
O
C
T
A
N
R
C
A
E
N
R
S
F
C
O
A
R
R
M
E
Innovation:
.....................
Our Patients
.....................
H O P E
R e s e a r c h
&
I n n o v a t i o n
R e p o r t
2 0 0 9
Study Aims To Understand Optimal Surgical
Treatments for Younger Women With Breast Cancer
..........................................................................................................................................................
Heather Ann, 28, was a busy law student when she first felt a small, painful lump
the size of a pea in one of her breasts. Though her symptoms were more consistent
with a cyst, and her younger age statistically meant she was at low risk, Heather
Ann was diagnosed with breast cancer the summer of her last year of law school.
“You’re in shock,” she says of her diagnosis. “It wasn’t a normal
sequence of thinking what’s next. I immediately thought treatment
could mean I might lose my breast. At the same time I also thought,
I’m so young and still single. What would life be like with only one
breast -- pre-marriage, pre-children, pre-job, pre-career?”
For her treatment, Heather Ann was referred to Dr. May Lynn Quan,
a breast surgical oncologist at the Odette Cancer Centre who
is leading research to better understand the most favourable
surgical options for younger women with breast cancer.
For the majority of women, who are over age 50 diagnosed with
breast cancer, an approach called breast-conserving therapy
(lumpectomy surgery followed by radiation treatment), has been
proven in large studies to be as effective as mastectomy (surgery
to remove the whole breast). Breast-conserving therapy instead of
the loss of the entire breast is also generally preferred, if deemed
a safe option.
In younger women, the effectiveness of breast conserving therapy
compared to mastectomy is less understood.
“Young women with breast cancer are at higher risk of recurrence
8
............................................................
P U R P O S E
C a n c e r
and have poorer outcomes compared to older women. Our study
aims to identify stronger predictors of recurrence in younger women
where mastectomy would be more appropriate and conversely, to
identify women at lower risk for whom breast conserving therapy
would be as effective,” says Dr. Quan, assistant professor, Departments of Surgery and Health Policy, Management & Evaluation,
University of Toronto. Mastectomy at any age impacts significantly
on quality of life but issues such as capability for breast feeding,
sexuality and body image are particularly relevant to young women.
The study led by Dr. Quan and funded by the Canadian Breast
Cancer Foundation, examines the treatments and outcomes of
1,800 women, age 35 or younger who were diagnosed with breast
cancer between 1994 and 2003. Dr. Quan hopes to identify criteria
more unique to recurrence and mortality risk in younger women to
help better identify their best surgical options.
Despite being diagnosed in her last year of law school, a resilient
and determined Heather Ann worked throughout her diagnosis and
treatment, and with the strong support of her family, friends – and
Dr. Quan – she completed law school on time and with all credits.
P u r p o s e
“It is a privilege to be a part
of a highly skilled and
specialized team with
world-class expertise. I find
it fulfilling to be able to
address issues we see in
clinic through our research,
with the hope we can make
a difference in the lives of
our patients.”
Dr. May Lynn Quan (left)
H o p e
“I was really comforted by
how much support I had
from everyone involved in
my care – the warm smiles,
the receptivity. That support
gave me the trust and the
confidence that, at the ‘end
of the day’, it was going to
be okay.”
Heather Ann (right)
R e s e a r c h
&
I n n o v a t i o n
R e p o r t
2 0 0 9
Targeted, High Intensity Treatments
Show Promise in Prostate Cancer
..........................................................................................................................................................
When Bradley Brown, 68, discovered he had prostate cancer, he was encouraged
when his doctor said he’d be a perfect candidate for a new treatment option that
could offer effective disease control and minimal risk of side effects, all with fewer
than usual treatment sessions.
After a biopsy indicated low-risk prostate cancer, he and Dr. Andrew
Loblaw discussed a study involving 84 low-risk prostate cancer
patients, underway at the Odette Cancer Centre testing what
Loblaw calls the “cure without compromise.”
“He explained to me that they would plant three or four gold seeds
and do a CT scan to know the exact architecture of my prostate,”
says Bradley, a consultant to the automotive industry. “They would
then target the prostate, which is the size of a walnut, and come
within 4 millimeters of its edge.”
H O P E
In doing so, many of the potential side effects of standard
radiation can be avoided. At the same time, Bradley’s treatment
would be given in higher doses per day and higher total doses,
known as hypofractionation.
This combination paired with a new imaging technique meant
fewer treatments – five weekly treatments versus 38 treatments, 5
times per week over two months, says Dr. Loblaw, head of Clinical Trials and Epidemiology, Odette Cancer Centre, and director of
research, Department of Radiation Oncology, Sunnybrook Health
Sciences Centre.
Odette Cancer Centre radiation oncologist Dr. Patrick Cheung,
who is leading the study with Loblaw, notes that a key benefit is
side effects seem to be extremely rare despite the higher dose.
1 0
.....................................................................
P U R P O S E
C a n c e r
He says the new approach is also being tested in patients who
have seen their cancer return despite prostate removal. Imageguided radiation therapy is also being explored in more than 200
patients with advanced prostate cancer, and a study may be on
the horizon to use even higher doses in patients with intermediate-risk prostate cancer. Funding for the research is partially
provided by the Canadian Association of Radiation Oncologists,
and the National Cancer Institute of Canada.
“The consistent theme is using image guidance and hypofractionation to finish treatment faster, hopefully with better cure rates,”
says Cheung. “We want to be leaders in exploring the approach in
all stages of prostate cancer. There has been quite a bit of interest
in our work from many centres of excellence. My guess is there will
be a move [in the field] that less -- is more.”
Loblaw notes that efforts are also underway to explore the use of
small beacons in place of the gold seeds that will function as a kind
of “global positioning system for the prostate”, helping to ensure
treatment is delivered more accurately. As well, a new treatment
system will hopefully ultimately allow for dose delivery in threeminute sessions instead of the usual 20.
“It was remarkably simple,” says Bradley, of his treatment. “My
PSA is now 0.4 and I have no need for surgery.”
P u r p o s e
"Working with dedicated
and caring physicians at
the Odette, inspires me to
provide better care for my
patients today and drive our
research to provide better
care for those we'll be seeing
in the future. Together I
believe we can achieve
"cure without compromise".
Dr. Andrew Loblaw (right)
H o p e
“Dr. Loblaw is an
outstanding caregiver.
The time he spends
with his patients is
truly remarkable…
The Odette Cancer Centre
is such a caring place.”
Brad (left)
H O P E
R e s e a r c h
&
I n n o v a t i o n
R e p o r t
2 0 0 9
Long-term, Low-dose ‘Metronomic’ Anti-cancer
Chemotherapy for Effective Cancer Control
..........................................................................................................................................................
Angiogenesis is a natural process that happens in the body to heal wounds and
involves the growth of new blood vessels from pre-existing ones through a
balanced series of on/ off switches.
In cancer or tumour angiogenesis, these switches are no longer
regulated properly by the body, and blood flow increases to the
cancer, a process critical to its continued growth and spread.
Greater understanding of tumour angiogenesis has led to developments in antiangiogenic drug therapies, shown to inhibit tumour
growth by blocking blood flow to the cancer.
Dr. Robert Kerbel, senior scientist, Sunnybrook Research Institute
and Canada Research Chair in Tumour Biology, Angiogenesis and
Antiangiogenic Therapy, is an internationally renowned trailblazer
in the study of tumour angiogenesis and antiangiogenic therapy.
He and his lab are leading innovations in the field.
He is working closely with Odette Cancer Centre medical oncologists
to translate into clinical care a concept he pioneered called
antiangiogenic ‘metronomic’ chemotherapy. Like a metronome that
produces a steady, user-defined beat, metronomic chemotherapy
involves close, regular, long-term administration of low-doses of
drug therapies with a goal for better tolerance, reduced side effects
and effective control in the treatment of several types of cancer.
The thought is that metronomic chemotherapy targets the cells
lining the blood vessels growing into the tumours, more than the
tumours themselves, and thus acts as an antiangiogenic treatment.
“We are committed to maintaining or improving the effectiveness
of anti-cancer chemotherapy drugs while reducing their toxic side
1 2
.........................................................................
P U R P O S E
C a n c e r
effects, to contribute to improved quality of life as well as reduce
costs,” says Dr. Kerbel.
Dr. Kerbel is collaborating with Dr. Rena Buckstein, hematologist, Odette Cancer Centre and associate scientist, Sunnybrook
Research Institute, who conducted a Phase II clinical trial of
high-dose Celecoxib (anti-inflammatory arthritis medication) and
low-dose metronomic Cyclophosphamide therapy for patients with
relapsed and refractory aggressive non-Hodgkin’s Lymphoma.
Cyclophosphamide is a well-known chemotherapy drug usually
given in higher doses. In contrast, in the trial it was given every day
at very low doses, by tablet.
Dimitar Petkovski, 70, was diagnosed with relapsed non-Hodgkin’s
Lymphoma in 2007 and is currently on this combination therapy.
“So far I’m doing okay. I’m feeling good. Overall, my health is
improving and I’m very pleased,” says Dimitar, who specifically
chose Sunnybrook for his care. Dr. Buckstein reports that he, like
many patients in the published trial, is responding and tolerating
the therapy extremely well with few side effects. “Although shrinking
of the tumours is the goal, we are satisfied if we achieve stable
disease for these individuals and help extend their lives.”
Says Dr. Kerbel, whose foundational basic research in angiogenesis
and antiangiogenic therapies is approaching translation to clinical
care, “The dialogue between scientists and clinicians and our
collaborations are constant – towards improved quality of life.”
P u r p o s e
“We are committed
to maintaining the
effectiveness of
anti-cancer drugs while
reducing toxic side
effects, to contribute
to improved quality
of life.”
Dr. Robert Kerbel (left)
Dr. Rena Buckstein (right)
H o p e
“I encourage anyone
who is sick, not to
fear the illness, but
to focus on how they
can be helped – how
they can be improved.”
Dimitar (centre)
H O P E
R e s e a r c h
&
I n n o v a t i o n
R e p o r t
2 0 0 9
Caring for the Whole Patient:
Body, Mind and Spirit
..........................................................................................................................................................
Living with cancer extends beyond the body, affecting everything from relationships
and emotional health to one’s personal finances. Margaret Fitch is at the forefront
of efforts to meet the multifaceted non-medical needs of cancer patients and their
families at the Odette Cancer Centre.
“As human beings, we are more than physical entities,” says Fitch,
co-lead of the Centre’s new Integrated Psychosocial, Supportive
and Palliative Care program with Dr. Jeff Myers. “We are multidimensional – with emotional, psychological, social and spiritual
needs. Cancer has an impact on every one of these dimensions
and health-care providers need to pay attention to all of them.”
Fitch is a recognized national leader in the field of supportive care
which encompasses services to help cancer patients cope with
their illness and maintain quality of life. In 1994, Fitch developed a
Supportive Care Framework. Over the last 15 years, Fitch’s model
has been validated by a growing body of research on patients’
needs during their journey through the cancer care system. The
Framework comprises nine key services that should be made
available to cancer patients and their families: orientation to
the cancer centre and cancer care system, emotional support,
psycho-educational resources, adjustment counselling, crisis
intervention, nutritional intervention, psychotherapy, pain/symptom
management and practical assistance with issues of daily living.
The Odette Cancer Centre’s Integrated Psychosocial, Supportive
and Palliative Care Program builds on Fitch’s original Framework
1 4
.............................................................
P U R P O S E
C a n c e r
and brings together a multidisciplinary group of professionals
dedicated to support the patient through their cancer experience.
The team includes representatives from psychology, social work,
nutritional science, palliative care, physiotherapy, occupational
therapy and speech pathology.
“Everyone was so helpful, kind and caring,” says Donna Farrage
who after treatment for her breast cancer, sought additional
support of nutritional counselling services and psychology
services within the Integrated Psychosocial, Supportive and
Palliative Care program. Patients can also access individual and
group counselling with social workers for example. They might
also seek support from the Lymphedema Clinic, or consult with the
Centre’s Drug Reimbursement Counsellor about how to navigate
the complex claims process.
“We have an expert cadre of professionals in this program who,
in a truly collaborative way, are committed to meeting the wide
spectrum of needs of people living with cancer,” says Fitch, head
of Oncology Nursing, Odette Cancer Centre.
P u r p o s e
“Working here offers the
opportunity to make a
difference. Cancer and
treatments have such an
impact on individuals and
families. If I can help reduce
the burden and add to
improved quality of life, my
knowledge and skills are
used to full advantage.”
Marg Fitch (right)
H o p e
“Everyone is so helpful and
kind. Sunnybrook is such as
caring place. Even during
my check-ups at the Cancer
Centre – it’s like an
extended family – I often
reconnect with staff who
were there for me during
treatments.”
Donna Farrage (left)
H O P E
R e s e a r c h
&
I n n o v a t i o n
R e p o r t
2 0 0 9
Head and Neck Cancer: Using PET
Scans to Monitor Treatment Effect
..........................................................................................................................................................
Frank Ennis, 50, began having trouble swallowing in April 2008. After a biopsy on
the lymph node on the right side of his neck indicated advanced neck cancer, he
began a three-month regimen of radiation and chemotherapy.
During his treatment, Frank participated in a study using positron
emission tomography (PET) to monitor the effects of treatment on
the tumour.
With the addition of extra radiation or chemotherapy, studies show
that more patients with advanced head and neck cancer achieve
a higher cure rate, however with more severe side effects. The
challenge is to accurately determine the response of the cancer
early so treatment can be better tailored to each patient.
Dr. Ian Poon, radiation oncologist, Odette Cancer Centre and
associate scientist, Sunnybrook Research Institute, is leading this
PET study to find a way to gauge how patients are doing while
receiving treatment. “If the cancer is very likely to recur, or is not
responding, we could arguably stop radiation treatment and go
straight to surgical options. In cases where we are seeing an
excellent response— in the future, we might be able to reduce
the intensity of the treatment with less radiation or chemotherapy
treatments.”
PET can identify physiologic or metabolic abnormalities not just
physical distortions in anatomy that occur later, after cell death.
The nuclear imaging technology involves injecting the body with
radioactive sugar, known as 2-[F-18] fluora-2-deoxy-D-glucose
(FDG). Tumours become visible in contrast to normal tissue because
they take up more sugar.
1 6
......................................................................
P U R P O S E
C a n c e r
The three-year observational study started in fall 2008 and is a
joint study with Sunnybrook’s Odette Cancer Centre and Juravinski
Cancer Centre in Hamilton, Ont. “The study will involve 100 patients
with advanced head and neck cancers,” says Dr. Poon, lead for the
Head and Neck Cancer Care Team, Odette Cancer Centre. “They
will receive radiation therapy and or chemotherapy and have a PET
scan prior to the start of the study and three weeks in, to determine
if PET along with other variables can accurately help predict
treatment success, thereby influencing disease management.”
Participating in the study did not influence Frank’s treatment, but
he was happy to be involved since the results could ultimately
benefit others. Treatment response in Frank’s case was considered dramatic. There are currently no signs of cancer cells, though
his condition will continue to be monitored with MRI (magnetic
resonance imaging). Despite some side effects to his hearing and
salivary glands, Frank has returned to work.
”From the first time I walked through the doors of the T-Wing I was
treated with a kindness, patience, and an often essential sense of
humour -- that went beyond just being professional. The doctors
and nurses were there when I needed them,” says Frank.
P u r p o s e
"I have a greater sense of
purpose - of fulfillment
here – to be part of a new
direction, and most
importantly to be part of a
team that is making an
impact on people’s lives
through continuously
better treatments and
approaches."
Dr. Ian Poon (right)
H o p e
"My parents died of cancer
over 25 years ago. The
diagnosis of cancer had,
at that time, very little in
the way of hope. The
advances made in research
over the intervening years
means hope is now, for
me, not wishful thinking
but a reality.”
Frank (left)
.......................................................................................................................
Major Sources of External Funding
2007-2008: Cancer Program
............................................................
.......................................................................................................................
$28.2 million
3%
Canada Foundation for Innovation
15% Canadian Institutes of Health Research
20% Donations & Trust Income
6%
Foundations
9%
Industry
4%
Ministry of Research and Innovation
12% National Cancer Institute of Canada
5%
National Institutes of Health
12% Ontario Institute for Cancer Research
1 8
6%
Other Funding Sources
8%
Other Government Sources
At The Centre
........................................................................................................ .....................
Innovation
of Our Cancer
.....................
Research and
........................................................................................................ .....................
I
N
N
O
V A T
I
O
N
I
C
A
N
R
M
E
O
D
D
E
E
L
L
I
S
V
O
E
F
R Y
Innovation:
.....................
Our Patients
.....................
H O P E
R e s e a r c h
&
I n n o v a t i o n
R e p o r t
2 0 0 9
Technological Solution Enhances
Multidisciplinary Cancer Care
..........................................................................................................................................................
On any given day at the Odette Cancer Centre, you will find cancer care professionals
from diverse specialties sitting around a table discussing treatment plans for new
patients. These Multidisciplinary Cancer Conferences may look like your average
business meeting, but they are anything but.
By optimizing the wealth of expertise at the Centre, the
conferences are leading-edge tools for ensuring the best possible
patient care. Now, with a simple technological innovation, Dr.
Mahmoud Khalifa has found a way to make Multidisciplinary
Cancer Conferences even more effective.
Each Odette Cancer Centre disease site group or Cancer Care
Team holds its own weekly conference, where the experts
thoroughly examine new patients’ cases before coming to a consensus on the best treatment. Depending on the cases for review,
the specialties involved could include pathology, radiology,
surgical oncology, nursing, pharmacy and occupational therapy
– to name just a few.
Traditionally, the participants at a Multidisciplinary Cancer Conference would take individual notes on the meeting’s discussions and
clinical decisions. “Those untraceable sheets of paper could not
facilitate the most successful quality improvement initiatives,” says
Dr. Khalifa, director of Surgical Pathology at Sunnybrook Health
Sciences Centre. Seeing there must be a better way, he developed
a Multidisciplinary Cancer Conferences database in 2006 that can
be customized to meet the needs of different disease site groups.
The Multidisciplinary Cancer Conferences database is the first of
its kind in Canada and one of a handful in the world. It holds a
2 0
....................................................................
P U R P O S E
C a n c e r
secure archive of conference proceedings, allowing for easy monitoring of treatment recommendations and creating opportunities
for quality improvement projects. “The system is user-friendly and
allows us to quickly go back and check a permanent record when
we need to,” says Dr. Allan Covens, a surgical oncologist and lead,
Gynaecological Cancer Care Team at the Odette Cancer Centre.
The database also enables a more efficient sharing of expertise
among conference participants by generating a list of cases along
with relevant diagnostic information in advance of each meeting.
“Everyone arrives fully prepared and ready to discuss the cases
in depth,” says Dr. Khalifa, a professor in the Departments of
Laboratory Medicine & Pathobiology, and Obstetrics and Gynecology,
University of Toronto.
Currently, five different Cancer Care Teams at the Odette Cancer
Centre use the system, with future plans for use across the Centre.
Cancer Care Ontario has also expressed interest in using the
principles of the database to help implement Multidisciplinary
Cancer Conferences across the province.
Dr. Khalifa’s next goal is to move the database to a secure website.
“This system has consolidated our multidisciplinary approach to
patient care, making it more efficient and effective,” he says, “and
we want to support its development in whatever way we can.”
P u r p o s e
“This system has consolidated
our multidisciplinary
approach to patient care,
making it more efficient
and effective, and we want
to support its development
in whatever way we can.”
Dr. Mahmoud Khalifa
.......................................................................................................................
Proportion of Total External Funding
2007-2008: Cancer Program
.........................................................
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. ..
$28.2 million of $54.9 million
51% Cancer Research Program
49% Other Sunnybrook
Research Programs
2 2
..
At The Centre
........................................................................................................ .....................
Initiatives
of Our Cancer
.....................
Research and
........................................................................................................ .....................
Innovation:
.....................
Our Patients
.....................
C a n c e r
R e s e a r c h
&
I n n o v a t i o n
R e p o r t
2 0 0 9
The Ongoing Support Of Funding Partners Is Vital To Continued
Advancements In Cancer Research And Tailored Treatments.
Sunnybrook’s Odette Cancer Centre in collaboration with Sunnybrook Research Institute
focuses on translation research with the strongest potential for direct impact on clinical care.
Research ranges from basic science at the molecular level to better identify for example risk
and recurrence markers, to imaging research to develop and improve imaging modalities for
earlier detection, diagnosis, and more minimally invasive treatments.
Drs. Linda Rabeneck and Richard Wells with Peter Goodhand (centre) CEO,
Canadian Cancer Society, Ontario Division.
2 4
.........................................................
Funding partners continue to support the breadth of this cancer
research, and one such successful partnership is with the Canadian
Cancer Society. “We deeply appreciate the invaluable support of
funding partners like the Canadian Cancer Society, and look forward
to their continued awarding through a highly competitive peer-review
process,” says Dr. Richard Wells, Program Research Director,
Cancer, Sunnybrook.
Recently, the Canadian Cancer Society integrated their operations of
the National Cancer Institute of Canada to create the Canadian
Cancer Society Research Institute.
In the past five years, the Canadian Cancer Society has invested,
through its National Cancer Institute of Canada, over $6 million
across the spectrum of cancer research being conducted at
Sunnybrook, to include:
•
The work of Dr. Arun Seth and Dr. Robert Nam to confirm the
presence of an abnormal fusion gene, TMPRSS2:ERG as a
predictor of prostate cancer relapse in patients previously
treated with surgery. The goal is to identify patients to benefit
most from treatment, and to inform the development of targeted
therapeutic interventions.
•
Research conducted by Dr. Ellen Warner, Dr. Petrina Causer and
Dr. Don Plewes on the use of Magnetic Resonance Imaging
(MRI) for earlier and better detection of breast cancer in women
at high risk who have the BRCA1 or BRCA2 mutation.
Sunnybrook’s Odette Cancer Centre looks forward to the continued
support of the Canadian Cancer Society and other funding partners
who help propel cancer research, discovery and translation to further
transform cancer care.
Odette Cancer Centre Helps Lead Improvements
In Cancer Care In Ontario
There are two main provincial organizations, Cancer Care Ontario dedicated to developing
evidence-based best practices and standards in cancer care, and Ontario Institute for Cancer
Research dedicated to advancing cancer research. Sunnybrook’s Odette Cancer Centre staff
are proud of their contributing roles with these organizations, to continuously improve cancer
care and care delivery. Highlights of previous and current roles include:
•
•
Dr. Craig Earle, Ontario Institute for
Cancer Research, Translation Programs,
Program Leader, Health Services Research
Dr. Martin Yaffe, Ontario Institute for
Cancer Research, Research Programs,
Program Leader, One Millimetre Challenge
Guidelines And
Standards Development
Cancer Care Ontario’s Programs in
Evidence-Based Care aim to improve the
quality of cancer care by helping apply
the best scientific evidence to practice.
•
•
•
•
•
•
•
•
Kathy Beattie: Systemic Therapy Workload
Development Team
Flay Charbonneau: Drug Formulary Team
Dr. Kevin Imrie: co-Chair, Hematology
Cancer Disease Site Group;
Dr. James Perry: co-Chair, Neuro-oncology
Cancer Disease Site Group
Dr. Teresa Petrella: co-Chair, Melanoma
Cancer Disease Site Group
Dr. Maureen Trudeau: Provincial Lead, Systemic
Treatment Program
Drs. Maureen Trudeau and Andrea Eisen:
co-Chairs, Breast Cancer Disease Site Group
Dr. Yee Ung, co-Chair, Lung Cancer
Disease Site Group
............................................................
The Ontario Institute for Cancer
Research is a centre of excellence
in cancer research with a focus on
prevention, early detection, diagnosis
and treatment of cancer.
............................................................
Research
Knowledge Transfer
Cancer Care Ontario acknowledges
the importance of disseminating the
best available evidence to enhance
the quality of cancer services.
•
•
•
•
•
•
Dr. Kevin Imrie: Chair, Advisory Panel on
Bone Marrow and Stem
Cell Transplantation
Dr. Mahmoud Khalifa: Quality Improvements
for Cancer Pathology Reporting
Dr. Jeff Myers: co-Chair, Provincial
Working Group, Models of Palliative
Care Delivery
Dr. Andy Smith, Dr. Calvin Law, Dr. Frances
Wright, Anna Gagliardi, Linda Last:
Coordinated Improvement in Colorectal
Cancer Practice and Outcomes in Ontario
Dr. Ellen Warner: Chair, Expert
Panel on Clinical Practice Guidelines on
Magnetic Resonance Imaging Screening of
Women at High Risk for Breast Cancer
Dr. Frances Wright: Chair, Expert Panel on
Multidisciplinary Cancer Conference Standards
2 5
R e s e a r c h
&
I n n o v a t i o n
R e p o r t
2 0 0 9
Highlights
• American Society of Clinical Oncology (ASCO) Foundation Merit Award: Dr. C. Kelly
• Canadian Association of Medical Radiation Technologists Conference Philips
Award: Karen Moline and Carol Gillies
• Canadian Association for Nursing in Oncology (CANO) Excellence in Oncology
Leadership: Eleanor Miller
• CANO/Astra Zeneca Reach for Excellence Award: Anne Blair
• Canadian Enterostomal Therapy Association President’s Award: Debbie Miller
• European Organisation for Research and Treatment of Cancer–National Cancer
Institute-ASCO Award: Dr. C. Kelly
• International Gynecologic Cancer Society Award for Excellence: Dr. Gillian Thomas
• Israel Cancer Research Fund Women of Action Award: Dr. Rena Buckstein
• Ministry of Research and Innovation Early Researcher Award: Dr. Robert Nam
• National Cancer Institute of Canada Cosbie Lecturer: Dr. Kathy Pritchard
• National Cancer Institute of Canada New Investigator Award: Dr. Natalie Coburn
• Royal College of Physicians and Surgeons of Canada Royal College Medal Award:
Dr. Robert Nam
• Sunnybrook, Bertin Award for Excellence in Customer Service: Malaika Kaunda
• Sunnybrook, Continuing Education Award for Excellence in Innovation at the
Peters-Boyd Academy: Dr. Scott Berry, Dr. Sunil Verma
• Sunnybrook, Department of Medicine, Senior Investigator Award:
Dr. Linda Rabeneck
• Sunnybrook, Department of Medicine, Senior Leadership Award:
Dr. Maureen Trudeau
• Sunnybrook, Patient Care Manager Excellence Award: Mary Glavassevich
• Sunnybrook, Schulich Awards Winners for Nursing & Clinical Excellence:
Elaine Avila, Anne Blair, Vera Hurlock
• Sunnybrook Research Institute Merit Award Winners: Dr. Dan Dumont,
Dr. Stuart Foster, Dr. Kullervo Hynynen, Dr. Robert Kerbel, Dr. Linda Rabeneck,
~
Dr. Jonathan Rast, Dr. Juan-Carlos Zúniga-Pflücker
• University of Toronto Peter Ellis Award: Neil D’Souza
2 6
......................................................................................
2008 Awards
................................................................................................................
C a n c e r
Tory Chair in Oncology
Research
Dr. Martin Yaffe is the new holder of the Tory Chair in Oncology
Research. He has made significant contributions in medical
imaging research, for earlier and more accurate detection of
several types of cancers. He is a senior scientist at Sunnybrook
Research Institute and a professor in the Departments of Medical
Biophysics and Medical Imaging at the University of Toronto.
Dr. Martin Yaffe
In appreciation of
......................................................................................................... .....................
Philanthropy
.........................................................................................................
T H A N K
Y O U
our donors’ support
.....................
in building an even
.....................
better cancer
.....................
centre for the many
.....................
communities
.....................
we serve.
C a n c e r
R e s e a r c h
&
I n n o v a t i o n
R e p o r t
2 0 0 9
Gloria Odette’s legacy of compassion will
transform the lives of others
..........................................................................................................................................................
In August of 2008, Sunnybrook lost a dear and wonderful friend, Gloria Odette,
a longtime supporter of the hospital and a cherished member of our community.
.....................................................................
2 8
Gloria was the anchor of the Odette family, whose generous support
has transformed Sunnybrook for almost a quarter of a century.
For 56 years, Gloria was the loving wife of Edmond, a behind-thescenes community leader who has been honoured with the Order
of Canada. Several buildings bear the family’s name, including the
Odette Cancer Centre which was named in 2007 to recognize the
couple’s landmark contributions to the future of cancer care at
Sunnybrook.
Edmond and Gloria have been an instrumental part of making
Sunnybrook the state-of-the-art patient care facility it is today.
Their daughter, Anne Odette Kaye, also supports the hospital as
a member of Sunnybrook Foundation’s Board of Directors, as
Chair of its Governing Council and as a member of the Breast
Cancer Campaign.
“Gloria gave from the heart, and always cared about making
a difference – for her family and friends, for the patients at
Sunnybrook, and to the community of which she was a part,”
says Kevin Goldthorp, CEO of Sunnybrook Foundation. “She
was an incredible person and a dedicated leader, and she will
be greatly missed.”
In 2008, cancer survivor and cycling champion, Lance Armstrong,
partnered with Sunnybrook to offer cyclists the once-in-a-lifetime
opportunity to join him on the roads of southwestern Ontario for a
120km ride. Forty cyclists took part in Ride with Lance, a unique
event benefitting both Sunnybrook’s Odette Cancer Centre and
Waterloo’s Grand River Regional Cancer Centre.
Participants raised at least $25,000 each and many of the
riders raised much more. Perry Dellelce, co-chair of the event
and Sunnybrook Foundation board member, was the top
fundraiser, raising $70,000 himself.
“The way the event came together was amazing,” says Perry.
“The camaraderie and friendships forged will not fade quickly.
I was overwhelmed by the way so many people joined together
in support of a common cause. The funds raised are of vital
importance to staff and patients at Sunnybrook.”
The event raised over $1.4 million. The funds will support
clinical trials and the renovation and expansion of the pharmacy
and chemotherapy suites at the Odette Cancer Centre.
............................................................................................................
Ride with Lance
Jean helps our
researchers
find a cure
When Jean Loeffelhardt was diagnosed in 2007 with advancedstage colorectal cancer, the opinions of the experts she consulted
were unanimous: her best chance of survival lay with Dr. Andy
Smith, an internationally renowned oncologist, at Sunnybrook.
Jean immediately began an aggressive treatment regimen at
Sunnybrook and was thoroughly impressed by the professionalism
of Dr. Smith and the other doctors and nurses in her care team.
“As a patient, I felt empowered,” says Jean. “I was given the
perfect combination of technical information I needed to fully
participate in my treatment, mixed with the right amount of
human compassion.”
The treatment Jean received at Sunnybrook brought her cancer
into remission, giving her years of health before her cancer
eventually recurred.
“I am an American, and I could have gone to the United States
for treatment. I had a choice about where I wanted to be treated,
and for the quickest, most aggressive and advanced care, I
chose Sunnybrook.”
For Jean, her choice to donate to the Chair in Surgical Oncology
was personal – her gift supports the research that is making such
a difference in her life.
2 9
C a n c e r
R e s e a r c h
&
I n n o v a t i o n
R e p o r t
2 0 0 9
Upon first meeting Lillian Weinstock one is quickly warmed by her
wit, charm and generosity of spirit. She was born in Winnipeg and
moved to Toronto as a young adult to pursue her career goals.
Together, Lillian and her late husband Sydney built a booming
real estate business.
Twenty years ago, Lillian underwent a successful lumpectomy,
but in 2005 she was once again diagnosed with cancer at
Sunnybrook’s Odette Cancer Centre.
“When I was told I had cancer, I didn’t think it was useful to know
what type it was, and to this day I still don’t know,” says Lillian.
“I had enjoyed a wonderful life up to that point and I wanted to
continue to live – I just wanted the doctors to get rid of it.”
“Now, my cancer is in remission and I’m in good health,” says
Lillian. “I’m tremendously grateful to Dr. Rebecca Dent and Anne
Jack for the remarkable treatment they gave to me, and I know
that Sydney would be proud of my decision to give back to the
cancer centre.”
In appreciation of the treatment and care she has received over
the last four years, Lillian made a generous donation in support
of the Breast Cancer Site Group Clinical Trials, which will be part
of the new Breast Cancer Research Centre.
“My life is greatly blessed and I feel incredibly lucky to be in the
position to help the cancer centre provide treatment options for
patients battling cancer,” says Lillian. “If they can help me, it’s
only fitting that I do my part to help others.”
3 0
...............................................................................................................
Paying it forward:
A gift in
appreciation
of treatment
and care
A gift that
will give
patients
comfort
and care
Leda Krikorian was born and raised in Lebanon, where she had a
successful career as a molecular biologist. She was a devoted
wife, mother and friend and is fondly remembered by her children
Natasha, Nicholas and Nigel, and loving husband, Sarkis.
While in Lebanon in 2005, Mrs. Krikorian was diagnosed with lung
cancer, and at the insistence of her family returned to Toronto for
treatment and to be closer to her children.
She was treated by Dr. Sunil Verma at the Odette Cancer Centre,
and initially responded well to chemotherapy. But, the cancer
progressed. She passed away in 2007.
In her honour, a generous gift was made by the Leda Krikorian
Foundation to support the centre’s chemotherapy suites and
pharmacy renovation and expansion.
“We established the Foundation to help provide a comfortable environment for patients going through chemo,” explains Natasha. “Our
mother received excellent care at the cancer centre but experienced
discomfort while sitting in the chairs for treatments. We believe it’s
of utmost importance for basic comforts to be available for a stressfree patient experience.”
“My mother contributed to her community and to causes she believed in, but always shunned the spotlight,” says Nicholas. “She
would be proud and humbled that something so worthwhile has
been done in her honour.”
“Our mother lived a very full and beautiful life,” says Nigel. “She
was kind and caring, and we honour her memory by making this
gift to support the cancer centre.”
..
..
At The Centre
........................................................................................................ .....................
Success
of Our Cancer
.....................
Research and
........................................................................................................ .....................
P
U
B
L
I
C
A T
I
O
N
H
I
G
H
L
I
G
H
T
S
Innovation:
.....................
Our Patients
.....................
C a n c e r
R e s e a r c h
&
I n n o v a t i o n
R e p o r t
2 0 0 9
Publication Highlights
A Partial Summary of Full Publications from July 2007 to June 2008
Abel GA, Friese CR, Magazu LS, Richardson LC,
Fernandez ME, De Zengotita JJ, Earle CC. Delays
in referral and diagnosis for chronic hematologic
malignancies: a literature review. Leuk Lymphoma
2008;49(7):1352-9.
Al-Husaini H, Amir E, Fitzgerald B, Wright F,
Dent R, Fralick J, Clemons M. Prevalence of overt
metastases in locally advanced breast cancer. Clin
Oncol (R Coll Radiol) 2008;20(5):340-4.
Alibhai SM, Leach M, Kermalli H, Gupta V, Kowgier
ME, Tomlinson GA, Brandwein J, Buckstein
R, Minden MD. The impact of acute myeloid
leukemia and its treatment on quality of life and
functional status in older adults. Crit Rev Oncol
Hematol 2007;64(1):19-30.
Andrade-Souza YM, Ramani M, Beachey DJ, Scora
D, Tsao MN, Terbrugge K, Schwartz ML. Liquid
embolisation material reduces the delivered
radiation dose: a physical experiment. Acta
Neurochir 2008;150(2):161-4.
Antoniou AC, Cunningham AP, Peto J, Evans
DG, Lalloo F, Narod SA, Risch HA, Eyfjord JE,
Hopper JL, Southey MC, Olsson H, Johannsson
O, Borg A, Pasini B, Radice P, Manoukian S, Eccles
DM, Tang N, Olah E, Anton-Culver H, Warner E,
Lubinski J, Gronwald J, Gorski B, Tryggvadottir L,
Syrjakoski K, Kallioniemi OP, Eerola H, Nevanlinna
H, Pharoah PD, Easton DF. The BOADICEA model
of genetic susceptibility to breast and ovarian
cancers: updates and extensions. Br J Cancer
2008;98(8):1457-66.
3 2
Arnold AM, Seymour L, Smylie M, Ding K, Ung Y,
Findlay B, Lee CW, Djurfeldt M, Whitehead M, Ellis
P, Goss G, Chan A, Meharchand J, Alam Y, Gregg
R, Butts C, Langmuir P, Shepherd F. Phase II study
of vandetanib or placebo in small-cell lung cancer
patients after complete or partial response to
induction chemotherapy with or without radiation
therapy: National Cancer Institute of Canada
Clinical Trials Group Study BR.20. J Clin Oncol
2007;25(27):4278-4284.
tomography assessment in detecting uterine
perforation with intracavitary brachytherapy for
carcinoma of the cervix. Int J Gynecol Cancer
2007;17(4):821-6.
Awong G, La Motte-Mohs RN, Zúñiga-Pflücker
JC. Generation of pro-T cells in vitro: potential
for immune reconstitution. Semin Immunol
2007;19(5):341-9.
Basran PS, Woo MK. An Analysis of tolerance levels
in IMRT quality assurance procedures. Med Phys
2008;35(6):2300-7.
Barbera L, Paszat L, Qiu F. End-of-life care in
lung cancer patients in Ontario: aggressiveness
of care in the population and a description of
hospital admissions. J Pain Symptom Manage
2008;35(3):267-274.
Barbera L, Thomas G, Elit L, Covens A, Fyles A,
Osborne R, Yun L. Treating vulvar cancer in the
new millennium: are patients receiving optimal
care? Gynecol Oncol 2008;109(1):71-5.
Barbera L, Thomas G. Venous thromboembolism
in cervical cancer. Lancet Oncol 2008;9(1):54-60.
Barnes EA, Fan G, Harris K, Doyle M, Librach LS,
Chow E, Barbera L, Tsao M, Lam K, Danjoux C.
Involvement of family physicians in the care
of cancer patients seen in the palliative Rapid
Response Radiotherapy Program. J Clin Oncol
2007;25(36):5758-5762.
Barnes EA, Thomas G, Ackerman I, Barbera L,
Letourneau D, Lam K, Makhani N, Sankreacha R.
Prospective comparison of clinical and computed
Barrett K, Mistry N, Hayter C, Poldre P, Henry M,
Gardner S. The effectiveness of the Ivan H. Smith
Memorial Studentships program on encouraging
medical students to pursue a career in radiation
oncology. J Cancer Educ 2008;23(4):226-9.
Basran P, Yeboah C. Dosimetric verification of
micro-MLC based intensity modulated radiation
therapy. J App Clin Med Phys 2008;9(3):2832.
Berinstein NL. Enhancing cancer vaccines with
immunomodulators. Vaccine 2007;25 (Suppl 2):
B72-88.
Bernardini MQ, Covens A. Imaging of lymph node
metastases in cervical cancer. Can Med Assoc J
2008;178(7):867-9.
Berry SR. Just say die. J Clin Oncol 2008;26(1):157-9.
Berry SR, Hubay S, Soibelman H, Martin DK. The
effect of priority setting decisions for new cancer
drugs on medical oncologists’ practice in Ontario: a
qualitative study. BMC Health Serv Res 2007;7:193.
Bigenwald RZ, Warner E, Gunasekara A, Hill
KA, Causer PA, Messner SJ, Eisen A, Plewes DB,
Narod SA, Zhang L, Yaffe MJ. Is mammography
adequate for screening women with inherited
BRCA mutations and low breast density? Cancer
Epidemiol Biomarkers Prev 2008;17(3):706-11.
Blackmore KM, Knight JA, Jong R, Lilfe L. Assessing
breast tissue density by transillumination breast
spectroscopy (TIBS): an intermediate indicator of
cancer risk. Br J Radiol 2007;80(955):545-6.
Ride with Lance
Booth CM, Clemons M, Dranitsaris G, Joy A,
Young S, Callaghan W, Trudeau M, Petrella T.
Chemotherapy-induced nausea and vomiting in
breast cancer patients: a prospective observational
study. J Support Oncol 2007;5(8):374-80.
Bos R, van Duikeren S, van Hall, T, Lauwen MM,
Parrington M, Berinstein NL, McNeil B, Melief
CJ, Verbeek JS, van der Burg SH, Offringa R.
Characterization of antigen-specific immune
responses induced by canarypox virus vaccines. J
Immunol 2007;179(9):6115-22.
Boyes A, Tang K, Yaffe M, Sugar L, Chopra R,
Bronskill M. Prostate tissue analysis immediately
following magnetic resonance imaging guided
transurethral ultrasound thermal therapy. J Urol
2007;178 (23 Pt 1):1080-5.
Bradley NM, Husted J, Sey MS, Sinclair E, Li KK,
Husain AF, Danjoux C, Barnes EA, Tsao MN, Barbera
L, Harris K, Chiu H, Doyle M, Chow E. Did the
pattern of practice in the prescription of palliative
radiotherapy for the treatment of uncomplicated
bone metastases change between 1999 and 2005
at the rapid response radiotherapy program? Clin
Oncol (R Coll Radiol) 2008;20(5):327-6.
Brandt MG, Higgins KM: Secondary renal cell
carcinoma of the head and neck. J Otolaryngol
2007;36(6):E85-7.
Bruchovsky N, Klotz L, Crook J, Phillips N, Abersbach
J, Goldenberg SL: Quality of life, morbidity, and
mortality results of a prospective phase II study of
intermittent androgen suppression for men with
evidence of prostate-specific antigen relapse after
radiation therapy for locally advanced prostate
cancer. Clin Genitourin Cancer 2008;6(1):46-52.
Buckstein R, Meyer, RM Seymour L, Biagi J, Mackay
H, Laurie S, Eisenhauer E. Phase II testing of
sunitinib: the National Cancer Institute of Canada
Clinical Trials Group IND. Program Trials IND.182185. Curr Oncol 2007;14(4):154-61.
Capurro MI, Xu P, Shi W, Li F, Jia A, Filmus J.
Glypican-3 inhibits Hedgehog signaling during
development by competing with Hedgehog
binding. Dev Cell 2008;14(5):700-11.
Cardella J, Coburn NG, Gagliardi A, Maier BA, Greco
E, Last L, Smith AJ, Law C, Wright F. Compliance,
attitudes and barriers to post-operative colorectal
cancer follow-up. J Eval Clin Pract 2008;14(3):407-15.
Cashman R, Bernstein LJ, Bilodeau D, Bovett G,
Jackson B, Yousefi M, Prica A, Perry J. Evaluation
of an educational program for the caregivers of
persons diagnosed with a malignant glioma. Can
Oncol Nurs J 2007;17(1):6-15.
Causer PA, Jong RA, Warner E, Hill K, Wong JW,
Curpen BN, Plewes DB. Breast cancers detected
with imaging screening in the BRCA population:
emphasis on MR imaging with histopathologic
correlation. Radiographics 2007;27(Suppl1):S165-82.
Chakraborty A, Wells R, Doherty M, Huynh C, Selby
D. Joint pain in AML: Successful pain control
with radiotherapy. J Pain Symptom Manage
2008;35(6):670-2.
Chan LS, Wells RA. Manipulation of reciprocal salt
bridges at the heterodimerization interface alters
the dimerization properties of mouse RXRalpha
and PPARgamma1. Biochem Biophys Res Commun
2007;358(4):1080-5.
Cheung K, Couture O, Bevan PD, Cherin E, Williams
R, Burns PN, Foster FS. In vitro characterization of
the subharmonic ultrasound signal from Definity
microbubbles at high frequencies. Phys Med Biol
2008;53(5);1209-23.
Cheung MC, Imrie KR. Targeting the follicular
lymphoma microenvironment - ready for primetime? Leuk Lymphoma 2008;49(5):837-8.
Cheung MC, Imrie KR, Leitch HA, Park-Wyllie LY,
Buckstein R, Antoniou T, Loutfy MR. Physician
perceptions and preferences in the treatment of
acquired immunodeficiency syndrome (AIDS)related lymphoma. Ann Hematol 2007;86(9):631-8.
Choo R, Danjoux C, Morton G, Szumacher E, Sugar
L, Gardner S, Kim M, Choo CM, Klotz L. How much
does Gleason grade of follow-up biopsy differ from
that of initial biopsy in untreated, Gleason score
4-7, clinically localized prostate cancer? Prostate
2007;67(15):1614-20.
Choo R, Pearce A, Danjoux C, Morton G, Deboer
G, Szumacher E, Loblaw A, Cheung P. Prospective
evaluation of quality of life in prostate cancer
patients receiving combined treatment of
postoperative radiotherapy plus androgen
suppression for PT3 or positive resection
margin after radical prostatectomy. Eur Urol
2007;52(6):1645-50.
Chopra R, Baker N, Choy V, Boyes A, Tang K,
Bradwell D, Bronskill MJ. MRI-compatible
transurethral ultrasound system for the treatment
of localized prostate cancer using rotational
control. Med Phys 2008;35(4):1346-57.
Chow E, Fan G, Hadi S, Filipczak L. Symptom
clusters in cancer patients with bone metastases.
Support Care Cancer 2007;15(9):1035-43.
Chow E, Fan G, Hadi S, Wong J, Kirou-Mauro A,
Filipczak L. Symptom clusters in cancer patients
with brain metastases. Clin Oncol (R Coll Radiol)
2008;20(1):76-82.
Chow E, Harris K, Fan G, Tsao M, Sze WM. Palliative
radiotherapy trials for bone metastases: a
systematic review. J Clin Oncol 2007;25(11):1423-36.
3 3
C a n c e r
R e s e a r c h
&
I n n o v a t i o n
Publication Highlights
Chuang C, Sahgal A, Lee L, Larson D, Huang K, Petti
P, Verhey L, Ma L. Effects of residual target motion
for image-tracked spine radiosurgery. Med Phys
2007;34(11):4484-90.
Clarke M, Coates AS, Darby SC, Davies C, Gelber
RD, Godwin J, Goldhirsch A, Gray R, Peto R,
Pritchard KI, Wood WC. Adjuvant chemotherapy in
oestrogen-receptor-poor breast cancer: patientlevel meta-analysis of randomised trials. Lancet
2008;371(9606):29-40.
Clarke GM, Zubovits JT, Katic M, Peressotti C, Yaffe
MJ. Spatial resolution requirements for acquistion
of the virtual screening slide for digital wholespecimen breast histopathology. Hum Pathol
2007;38(12):1764-71.
Coburn N, Fulton J, Pearlman DN, Law C, DiPaolo B,
Cady B. Treatment variation by insurance status for
breast cancer patients. Breast J 2008;14(2):128-34.
Coburn NG, Govindarajan A, Law CH, Guller U, Kiss
A, Ringash J, Swallow CJ, Baxter NN. Stage-specific
effect of adjuvant therapy following gastric cancer
resection: a population-based analysis of 4,041
patients. Ann Surg Oncol 2008;15(2):500-7.
Coburn NG, Guller U, Baxter NN, Kiss A, Ringash J,
Swallow CJ, Law CH. Adjuvant therapy for resected
gastric cancer--rapid, yet incomplete adoption
following results of intergroup 0116 trial. Int J
Radiat Oncol Biol Phys 2008;70(4):1073-80.
Come SE, Buzdar AU, Ingle JN, Johnston SR, Brodie
AM, Coombes RC, Miller WR, Pritchard KI, Winer
EP, Zujewski JA, Goss PE. Endocrine and targeted
manipulation of breast cancer: summary statement
for the Sixth Cambridge Conference. Cancer
2008;112(3 Suppl):673-8.
3 4
R e p o r t
2 0 0 9
A Partial Summary of Full Publications from July 2007 to June 2008
Crump M, Gluck S, Tu D, Stewart D, Levine M,
Kirkbride P, Dancey J, O’Reilly S, Shore T, Couban
S, Girouard C, Marlin S, Shepherd L, Pritchard KI.
Randomized trial of high-dose chemotherapy with
autologous peripheral-blood stem-cell support
compared with standard-dose chemotherapy in
women with metastatic breast cancer: NCIC MA.16.
J Clin Oncol 2008;26(1):37-43.
Cuppone F, Bria E, Verma S, Pritchard KI, Gandhi
S, Carlini P, Milella M, Nistico C, Terzoli E, Cognetti
F, Giannarelli D. Do adjuvant aromatase inhibitors
increase the cardiovascular risk in postmenopausal
women with early breast cancer? Meta-analysis of
randomized trials. Cancer 2008;112(2):260-7.
Curiel L, Chopra K, Hynynen K. Progress in
multimodality imaging: truly simultaneous
ultrasound and magnetic resonance imaging. IEEE
Trans Med Imaging 2007;26(12):1740-6.
Dahele M, Ung Y, Meharchand J, Shulman
H, Zeldin R, Behzadi A, Simone C, Cheng S,
Weigensberg C, Sivjee K. Integrating regional
and community lung cancer services to improve
patient care. Curr Oncol 2007;14(6):234-7.
Dahele MR, Ung YC. 18F-FDG PET in planning
radiation treatment of non-small cell lung
cancer: where exactly is the tumor? J Nucl Med
2007;48(8):1402.
Dalgorf D, Higgins KM, Ehrlich L.PET/CT fusion
technology: its role in managing recurrent, welldifferentiated thyroid cancer. Can J Surg 2008;
51(1):E21-2.
Dall’Era MA, Cooperberg MR, Chan JM, Davies
BJ, Albertsen PC, Klotz LH, Warlick CA, Holmberg
L, Bailey DE Jr, Wallace ME, Kantoff PW, Carroll,
PR. Active surveillance for early-stage prostate
cancer: review of the current literature. Cancer
2008;112(8):1650-9.
Danjoux C, Gardner S, Fitch M. Prospective
evaluation of fatigue during a course of curative
radiotherapy for localised prostate cancer. Support
Care Cancer 2007;15(10):1169-76.
Davey P, Schwartz ML, Scora D, Gardner S,
O’Brien PF. Fractionated (split dose) radiosurgery
in patients with recurrent brain metastases:
implications for survival. Br J Neurosurg
2007;21(5):491-5.
Dayes IS, Levine MN, Julian JA, Pritchard KI,
D’Souza DP, Kligman L, Reise D. Wiernikowski JA,
Bonilla L, Whelan TJ. Lymphedema in women with
breast cancer: characteristics of patients screened
for a randomized trial. Breast Cancer Res Treat
2008;110(2):337-42.
Dent S, Messersmith H, Trudeau M. Gemcitabine
in the management of metastatic breast cancer:
a systematic review. Breast Cancer Res Treat
2008;108(3):319-31.
Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn
HK, Sawka CA, Lickley LA, Rawlinson E, Sun P,
Narod SA. Triple-negative breast cancer: clinical
features and patterns of recurrence. Clin Cancer Res
2007;13(15 Pt 1):4429-34.
Dent R, Warner E. Screening for hereditary breast
cancer. Semin Oncol 2007;34(5):392-400.
Dhesy-Thind B, Pritchard KI, Messersmith H,
O’Malley F, Elavathil L, Trudeau M. HER2/neu in
systemic therapy for women with breast cancer:
a systematic review. Breast Cancer Res Treat
2008;109(2):209-29.
Disperati P, Hicks LK, Buckstein R. Rituximabinduced serum sickness in a patient with follicular
lymphoma. Leuk Lymphoma 2007;48(8):1633-5.
Ebos, JM, Lee CR, Bogdanovic E, Alami J, Van
Slyke P, Francia G, Xu P, Mutsaers AJ, Dumont DJ,
Kerbel RS. Vascular endothelial growth factormediated decrease in plasma soluble vascular
endothelial growth factor receptor-2 levels as a
surrogate biomarker for tumor growth. Cancer Res
2008;68(2):521-9.
Ride with Lance
Efficace F, Innominato PF, Bjarnason G, Coens
C, Humblet Y, Tumolo S, Genet D, Tampellini
M, Bottomley A, Garufi C, Focan C, Giacchetti
S, Levi F. Validation of patient’s self-reported
social functioning as an independent prognostic
factor for survival in metastatic colorectal cancer
patients: results of an international study by
the Chronotherapy Group of the European
Organisation for Research and Treatment of
Cancer. J Clin Oncol 2008;26(12):2020-6.
Eisen A, Trudeau M, Shelley W, Messersmith H,
Pritchard KI. Aromatase inhibitors in adjuvant
therapy for hormone receptor positive breast
cancer: a systematic review. Cancer Treat Rev
2008;34(2):157-74.
Fan G, Filipczak L, Chow E. Symptom clusters in
cancer patients: a review of the literature. Curr
Oncol 2007;14(5):173-9.
Gandhi S, Verma S. Aromatase inhibitors and
cardiac toxicity: getting to the heart of the matter.
Breast Cancer Res Treat 2007;106(1):1-9.
Findlay B, Tonkin K, Crump M, Norris B, Trudeau
M, Blackstein M, Burnell M, Skillings J, Bowman
D, Walde D, Levine M, Pritchard KI, Palmer MJ, Tu
D, Shepherd L. A dose escalation trial of adjuvant
cyclophosphamide and epirubicin in combination
with 5-fluorouracil using G-CSF support for
premenopausal women with breast cancer
involving four or more positive nodes. Ann Oncol
2007;18(10):1646-51.
Gerretsen P, Myers J. The physician: a secure base.
J Clin Oncol 2008;26(32):5294-6.
Flynn CJ, Yip D, Ko YJ, Yee A, Cardoso M, Bell C,
Aviv R, Chow E. Clinical benefit of reirradiation: a
case report. J Palliat Med 2008;11(1):112-116.
Fung-Kee-Fung M, Goubanova E, Sequeira K,
Abdulla A, Cook R, Crossley C, Langer B, Smith AJ,
Stern H. Development of communities of practice
to facilitate quality improvement initiatives in
surgical oncology. Qual Manag Health Care
2008;17(2):174-85.
El Demellawy D, Khalifa MA, Ismiil N, Wong S,
Ghorab Z. Primary colorectal small cell carcinoma:
A clinicopathological and immunohistochemical
study of 10 cases. Diagn Pathol 2007;2:35
Gagliardi AR, Fraser N, Wright FC, LemieuxCharles L, Davis D. Fostering knowledge exchange
between researchers and decision-makers:
Exploring the effectiveness of a mixed-methods
approach. Health Policy 2008;86(1):53-63.
El-Serag HB, Graham DY, Rabeneck L, Avid A,
Richardson P, Genta RM. Prevalence
and determinants of histological abnormalities
of the gastric cardia in volunteers. Scand J
Gastroenterol 2007;42:1158-66.
Gagliardi AR, Lemieux-Charles L, Brown AD,
Sullivan T, Goel V. Barriers to patient involvement
in health service planning and evaluation:
an exploratory study. Patient Educ Couns
2008;70(2):234-41.
Fairchild A, Goh P, Sinclair E, Barnes EA, Ghosh
S, Danjoux C, Barbera L, Tsao M, Chow E. Has
the pattern of practice in the prescription
of radiotherapy for the palliation of thoracic
symptoms changed between 1999 and 2006 at the
rapid response radiotherapy program? Int J Radiat
Oncol Biol Phys 2008;70(3):693-700.
Gagliardi AR, Wright FC, Anderson MA, Davis D.
The role of collegial interaction in continuing
professional development. J Contin Educ Health
Prof 2007;27(4):214-9.
Gagliardi AR, Wright FC, Khalifa MA, Smith AJ.
Multiple factors influence compliance with
colorectal cancer staging recommendations: An
exploratory study. BMC Health Serv Res 2008;8:34.
Giagounidis A, Fenaux P, Mufti GJ, Muus P,
Platzbecker U, Sanz G, Cripe L, Von LilienfeldToal M, Wells RA. Practical recommendations
on the use of lenalidomide in the management
of myelodysplastic syndromes. Ann Hematol
2008;87(5):345-52.
Gien LT, Covens A. Quality control in sentinel
lymph node biopsy in cervical cancer.
J Clin Oncol 2008;26(18):2930-1.
Gligorov J, Pritchard K, Goss P. Adjuvant and
extended adjuvant use of aromatase inhibitors:
Reducing the risk of recurrence and distant
metastasis. Breast 2007;16(Suppl 3):S1-9.
Gorey KM, Fung KY, Luginaah IN, Bartfay E, Hamm
C, Wright FC, Balagurusamy M, Mohammad A,
Holowaty EJ, Tany KX. Cancer Survival in Ontario,
1986-2003: Evidence of equitable advances across
most urban and rural places. Can J Pub Health
2008;99(1):12-16.
Goss PE, Ingle JN, Pater JL, Martino S, Robert NJ,
Muss HB, Piccart MJ, Castiglione M, Shepherd, LE,
Pritchard KI, Livingston RB, Davidson NE, Norton
L, Perez EA, Abrams JS, Cameron DA, Palmer MJ,
Tu D. Late extended adjuvant treatment with
letrozole improves outcome in women with
early-stage breast cancer who complete 5 years
of tamoxifen. J Clin Oncol 2008;26(12):1948-55.
Govindarajan A, Naimark D, Coburn NG, Smith
AJ, Law CHL. Use of colonic stents in emergent
malignant left colonic obstruction: A Markov
chain Monte Carlo decision analysis. Dis Colon
Rectum 2007;50(11):1811-24.
3 5
C a n c e r
R e s e a r c h
&
I n n o v a t i o n
Publication Highlights
Govindarajan A, Tan JC, Baxter NN, Coburn NG,
Law CH. Variations in surgical treatment and
outcomes of patients with pancreatic cancer:
a population-based study. Ann Surg Oncol
2008;15(1):175-85.
Grisaru D, Hauspy J, Prasad M, Albert M, Murphy
KJ, Covens A, Macgregor PF, Rosen B. Microarray
expression identification of differentially
expressed genes in serous epithelial ovarian
cancer compared with bulk normal ovarian
tissue and ovarian surface scrapings. Oncol Rep
2007;18(6):1347-56.
Grunfeld E, Urquhart R, Mykhalovskiy E, Folkes A,
Johnston G, Burge FI, Earle CC, Dent S. Toward
population-based indicators of quality end-oflife care: testing stakeholder agreement. Cancer
2008;112(10):2301-8.
Haas JS, Earle CC, Orav JE, Brawarsky P, Neville BA,
Williams DR. Racial segregation and disparities
in cancer stage for seniors. J Gen Intern Med
2008;23(5):699-705.
Hadi S, Fan G, Hird AE, Kirou-Mauro A, Filipczak
LA, Chow E. Symptom clusters in patients with
cancer with metastatic bone pain. J Palliat Med
2008;11(4):591-600.
Hamm C, Verma S, Petrella T, Bak K, Charette M.
Biochemotherapy for the treatment of metastatic
malignant melanoma: a systematic review. Cancer
Treat Rev 2008;34(2):145-56.
Hammond CM, White D, Tomic J, Shi Y, Spaner
DE. Extracellular calcium sensing promotes
human B-cell activation and function. Blood
2007;110(12):3985-95.
3 6
R e p o r t
2 0 0 9
A Partial Summary of Full Publications from July 2007 to June 2008
Harris K, Li K, Flynn C, Chow E. Worst, average
or current pain in the Brief Pain Inventory:
Which should be used to calculate the response
to palliative radiotherapy in patients with
bone metastases? Clin Oncol (R Coll Radiol)
2007;19(7):523-7.
Hauspy J, Beiner M, Harley I, Ehrlich L, Rasty G,
Covens A. Sentinel lymph node in vulvar cancer.
Cancer 2007;110(5):1015-23.
Helyer LK, O’Brien C, Coburn NG, Swallow CJ.
Surgeons’ knowledge of quality indicators
for gastric cancer surgery. Gastric Cancer
2007;10(4):205-14.
Hill KA, Rosen B, Shaw P, Causer PA, Warner E.
Incidental MRI detection of BRCA1-related solitary
peritoneal carcinoma during breast screening--A
case report. Gynecol Oncol 2007;107(1): 136-9.
Hilsden RJ, Tepper J, Moayyedi P, Rabeneck L. Who
provides gastrointestinal endoscopy in Canada?
Can J Gastroenterol 2007;21:843-6.
Hird AE, Wilson J, Symons S, Sinclair E, Davis
M, Chow E. Radiation recall dermatitis: case
report and review of the literature. Curr Oncol
2008;15(1):53-62.
Hofbauer GF, Baur T, Bonnet MC, Tartour E, Burg
G, Berinstein NL, Dummer R. Clinical phase I
intratumoral administration of two recombinant
ALVAC canarypox viruses expressing human
granulocyte-macrophage colony-stimulating
factor or interleukin-2: the transgene determines
the composition of the inflammatory infiltrate.
Melanoma Res 2008;18(2):104-11.
Holloway CM, Saskin R, Brackstone M, Paszat L.
Variation in the use of percutaneous biopsy for
diagnosis of breast abnormalities in Ontario. Ann
Surg Oncol 2007;14(10):2932-9.
Hunt DC, Tanioka K, Rowlands JA. X-ray imaging
using avalanche multiplication in amorphous
selenium: investigation of intrinsic avalanche noise.
Med Phys 2007;34(12):4654-63.
Hunter DM, Belev G, DeCrescenzo G, Kasap SO,
Mainprize JG, Rowlands JA, Smith C, Tümer T,
Verpakhovski V, Yin S, Yaffe MJ. The dependence of
the modulation transfer function on the blocking
layer thickness in amorphous selenium x-ray
detectors. Med Phys 2007;34(8):3358-73.
Hynynen, K. Focused ultrasound for blood-brain
disruption and delivery of therapeutic molecules into
the brain. Expert Opin Drug Deliv 2007;4(1):27-35.
Ingle JN, Tu D, Pater JL, Muss HB, Martino S,
Robert NJ, Piccart MJ, Castiglione M, Shepherd LE,
Pritchard KI, Livingston RB, Davidson NE, Norton
L, Perez EA, Abrams JS, Cameron DA, Palmer MJ,
Goss PE. Intent-to-treat analysis of the placebocontrolled trial of letrozole for extended adjuvant
therapy in early breast cancer: NCIC CTG MA.17.
Ann Oncol 2008;19(5):877-82.
Ismiil N, Rasty G, Ghorab Z, Nofech-Mozes S,
Bernardini M, Ackerman I, Thomas G, Covens A,
Khalifa MA. Adenomyosis involved by endometrial
adenocarcinoma is a significant risk factor for
deep myometrial invasion. Ann Diagn Pathol
2007;11(4):252-7.
Ismiil ND, Rasty G, Ghorab Z, Nofech-Mozes S,
Bernardini M, Thomas G, Ackerman I, Covens
A, Khalifa MA. Adenomyosis is associated with
myometrial invasion by FIGO 1 endometrial
adenocarcinoma. Int J Gynecol Pathol
2007;26(3):278-83.
Johnston S, Trudeau M, Kaufman B, Boussen H,
Blackwell K. LoRusso P, Lombardi DP, Ben Ahmed
S, Citrin DL, DeSilvio ML, Harris J, Westlund RE,
Salazar V, Zaks TZ, Spector NL. Phase II study
of predictive biomarker profiles for response
targeting human epidermal growth factor receptor
2 (HER-2) in advanced inflammatory breast
cancer with lapatinib monotherapy. J Clin Oncol
2008;26(7):1066-72.
Ride with Lance
Jonker DJ, O’Callaghan CJ, Karapetis CS, Zalcberg
JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ,
Tebbutt NC, van Hazel G, Wierzbicki R, Langer C,
Moore MJ. Cetuximab for the treatment of colorectal
cancer. N Engl J Med 2007;357(20):2040-8.
Kased N, Huang K, Nakamura JL, Sahgal A, Larson
DA, McDermott MW, Sneed PK. Gamma knife
radiosurgery for brainstem metastases: the UCSF
experience. J Neuro-oncol 2008;86(2):195-205.
Kassam Z, Wong RK, Ringash J, Ung Y, Kamra J,
DeBoer G, O’Brien M, Kim J, Loblaw DA, Wong S,
Cummings B, Davey P. A phase I/II study to evaluate
the toxicity and efficacy of accelerated fractionation
radiotherapy for the palliation of dysphagia from
carcinoma of the oesophagus. Clin Oncol (R Coll
Radiol) 2008;20(1):53-60.
Keller BM, Beachey DJ, Pignol JP. Experimental
measurement of radiological penumbra
associated with intermediate energy x-rays (1
MV) and small radiosurgery field sizes. Med Phys
2007;34(10):3996-4002.
Keller BM, Pignol JP, Rakovitch E, Sankreacha R,
O’Brien P. A radiation badge survey for family
members living with patients treated with a
(103)Pd permanent breast seed implant. Int J Radiat
Oncol Biol Phys 2008;70(1):267-71.
Keller BM, Peressotti C, Pignol JP. Optical imaging
analysis of microscopic radiation dose gradients
in Gafchromic EBT film using a digital microscope.
Med Phys 2008;35(8):3740-7.
Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J,
Ung YC, Lau DH, Crowley JJ, Gandara DR. Phase
III trial of maintenance gefitinib or placebo after
concurrent chemoradiotherapy and docetaxel
consolidation in inoperable stage III non-smallcell lung cancer: SWOG S0023. J Clin Oncol
2008;26(15):2450-2456.
Klotz L. Maximal androgen blockade for advanced
prostate cancer. Best Pract Res Clin Endocrinol
Metab 2008;22(2):331-40.
Kerr LM, Harrison MB, Medves J, Tranmer JE, Fitch
MI. Understanding the supportive care needs
of parents of children with cancer: an approach
to local needs assessment. J Pediatr Oncol Nurs
2007;24(5):279-93.
Klotz L. Editorial: Cumulative association of five
genetic variants with prostate cancer. Euro Urol
2008;53(6):1298-9.
Kinoshita M, Hynynen K. Key factors that affect
sonoporation efficiency in in vitro settings: the
importance of standing wave in sonoporation.
Biochem Biophys Res Commun 2007;359(10):860-5.
Klotz L. Point: Active surveillance for favorable
risk prostate cancer. J Natl Comp Canc Netw
2007;5(7):693-8.
Klotz L. Sunitinib, sorafenib and other systemic
noncytotoxic kidney cancer therapies can and
should be administered by urologists. Can Urol
Assoc J 2007;1(2 Suppl):S69-70.
Klotz L. Low risk prostate cancer can and should
often be managed with active surveillance and
selective delayed intervention. Nat Clin Pract Urol
2008;5(1):2-3.
Klotz L. Active surveillance for favorable risk
prostate cancer: Rationale, risks, and results. Urol
Oncol 2007;25(6):505-9.
Klotz L. Active surveillance for favorable risk
prostate cancer: Who, how, and why? Nat Clin
Pract Oncol 2007;4(12):692-8.
Klotz L. Active surveillance for favorable risk
prostate cancer: What are the results and how safe
is it? Semin Radiat Oncol 2008;18(1):2-6.
Klotz L. Nomogram for predicting survival in men
with clinically localized prostate cancer who do
not undergo definitive therapy. Nat Clin Pract Urol
2008;5(7):362-3.
Koprinarov I, Webster CA, MacDougall RD,
Rowlands JA. The x-ray light valve: a low-cost
digital radiographic imaging system. Med Phys
2007;34(12):4609-11.
Kotsopoulos J, Lubinski J, Lynch HT, Klijn J,
Ghadirian P, Neuhausen SL, Kim-Sing C, Foulkes
WD, Moller P, Isaacs C, Domchek S, Randall S, Offit
K, Tung N, Ainsworth P, Gershoni-Baruch R, Eisen
A, Daly M, Karlan B, Saal HM, Couch F, Pasini B,
Wagner T, Friedman E, Rennert G, Eng C, Weitzel
J, Sun P, Narod SA, Garber J, Osborne M, Fishman
D, McLennan J, McKinnon W, Merajver S, Olsson
H, Provencher D, Pasche B, Evans G, Meschino WS,
Lemire E, Chudley A, Rayson D, Bellati C. Age at first
birth and the risk of breast cancer in BRCA1 and
BRCA2 mutation carriers. Breast Cancer Res Treat
2007;105(2):221-8.
Kotsopoulos J, Zhang WW, Zhang S, McCready
D, Trudeau M, Zhang P, Sun P, Narod SA.
Polymorphisms in folate metabolizing enzymes
and transport proteins and the risk of breast
cancer. Breast Cancer Res Treat 2008;112(3):585-93.
Kouroukis CT, Chia S, Verma S, Robson D, Desbiens
C, Cripps C, Mikhael J. Canadian supportive
care recommendations for the management of
neutropenia in patients with cancer. Curr Oncol
2008;15(1):9-23.
3 7
C a n c e r
R e s e a r c h
&
I n n o v a t i o n
Publication Highlights
Kwon JS, Carey MS, Cook EF, Qiu F, Paszat LF. Are
there regional differences in gynecologic cancer
outcomes in the context of a single-payer, publiclyfunded health care system? A population-based
study. Can J Public Health 2008;99(3):221-26.
Lear W, Mittmann N, Barnes E, Breen D, Murray
C. Cost comparisons of managing complex facial
basal cell carcinoma: Canadian study. J Cutan Med
Surg 2008;12(2):82-7.
Leavens C, Williams R, Foster FS, Burns PN, Sherar
MD. Golay pulse encoding for microbubble
contrast imaging in ulrasound. IEEE Trans Ultrason
Ferroelectr Freq Control 2007;54(10);2082-90.
Lee, CW, Belanger K, Rao, SC, Petrella TM, Tozer
RG, Wood L, Savage KJ, Eisenhauer EA, Synold
TW, Wainman N, Seymour L. A phase II study of
ispinesib (SB-715992) in patients with metastatic or
recurrent malignant melanoma: a National Cancer
Institute of Canada Clinical Trials Group trial. Invest
New Drugs 2008;26(3):249-55.
Li KK, Hadi S, Kirou-Mauro A, Chow E. When should
we define the response rates in the treatment of
bone metastases by palliative radiotherapy? Clin
Oncol (R Coll Radiol) 2008;20(1):83-9.
Li KK, Harris K, Hadi S, Chow E. What should be the
optimal cut points for mild, moderate, and severe
pain? J Palliat Med 2007;10(6):1138-46.
Lim TS, Cheung PCF, Loblaw DA, Morton G, Sixel KE,
Pang G, Basran P, Zhang L, Tirona R, Szumacher E,
Danjoux C, Choo R, Thomas G. Hypofractionated
accelerated radiotherapy using concomitant
intensity-modulated radiotherapy boost technique
for localized high-risk prostate cancer: Acute toxic
results. Int J Radiat Oncol Biol Phys 2008;72(1):85-92.
3 8
R e p o r t
2 0 0 9
A Partial Summary of Full Publications from July 2007 to June 2008
Lo DS, Zeldin RA, Skrastins R, Fraser IM, Newman
H, Monavvari A, Ung YC, Joseph H, Downton T,
Maxwell L, Meharchand J. Time to treat: a system
redesign focusing on decreasing the time from
suspicion of lung cancer to diagnosis. J Thorac
Oncol 2007;2(11):1001-6.
Lopushinsky SR, Covarrubia KA, Rabeneck
L, Austin PC, Urbach DR. Accuracy of
administrative health data for the diagnosis of
upper gastrointestinal diseases. Surg Endosc
2007;21:1733-7.
Lu FG, Wong CS. Time-dependent neurosphereforming ability of adult rat spinal cord after
irradiation. Radiat Res 2007;168(4):453-61.
Mackey, JR, Clemons M, Cote MA, Delgado D,
Dent S, Paterson, A, Provencher L, Sawyer MB,
Verma S. Cardiac management during adjuvant
trastuzumab therapy: recommendations of the
Canadian Trastuzumab Working Group. Curr
Oncol 2008;15(1):24-35.
Martino TA, Tata N, Bjarnason GA, Straume M,
Sole MJ. Diurnal protein expression in blood
revealed by high throughput mass spectrometry
proteomics and implications for translational
medicine and body time of day. Am J Physiol
Regul Integr Comp Physiol 2007;293(3):R1430-7.
Meyerhardt JA, Zhu AX, Stuart K, Ryan DP,
Blaszkowsky L, Lehman N, Earle CC, Kulke
MH, Bhargava P, Fuchs CS. Phase-II study of
gemcitabine and cisplatin in patients with
metastatic biliary and gallbladder cancer. Dig Dis
Sci 2008;53(2):564-70.
Mintz A, Perry J, Spithoff K, Chambers A, Laperriere
N. Management of single brain metastasis: a
practice guideline. Curr Oncol 2007;14(4):131-43.
Morton GC, Sankreacha R, Halina P, Loblaw
A. A comparison of anatomy-based inverse
planning with simulated annealing and graphical
optimization for high-dose-rate prostate
brachytherapy. Brachytherapy 2008;7(1):12-16.
Muss HB, Tu D, Ingle JN, Martino S, Robert NJ, Pater
JL, Whelan TJ, Palmer MJ, Piccart MJ, Shepherd LE,
Pritchard KI, He Z, Goss PE. Efficacy, toxicity, and
quality of life in older women with early-stage
breast cancer treated with letrozole or placebo
after 5 years of tamoxifen: NCIC CTG intergroup
trial MA.17. J Clin Oncol 2008;26(12):1956-64.
Myers J, Shetty N. Going beyond efficacy:
strategies for cancer pain management. Curr Oncol
2008;15(Suppl 1):S41-9.
Nam RK, Zhang WW, Loblaw DA, Klotz LH,
Trachtenberg J, Jewett MA, Stanimirovic A, Davies
TO, Toi A, Venkateswaran V, Sugar L, Siminovitch
KA, Narod, SA. A genome-wide association screen
identifies regions on chromosomes 1q25 and 7p21
as risk loci for sporadic prostate cancer. Prostate
Cancer Prostatic Dis 2008;11(3):241-6.
Nam RK, Toi A, Klotz LH, Trachtenberg J, Jewett MA,
Appu S, Loblaw DA, Sugar L, Narod SA, Kattan MW.
Assessing individual risk for prostate cancer. J Clin
Oncol 2007;25(24):3582-8.
Nofech-Mozes S, Ackerman I, Ghorab Z, Ismiil N,
Thomas G, Covens A, Khalifa MA. Lymphovascular
invasion is a significant predictor for distant
recurrence in patients with early-stage endometrial
endometrioid adenocarcinoma. Am J Clin Pathol
2008;129(6):912-17.
Nofech-Mozes S, Ghorab Z, Ismiil N, Ackerman
I, Thomas G, Barbera L, Covens A, Khalifa MA.
Endometrial endometrioid adenocarcinoma: a
pathologic analysis of 827 consecutive cases. Am J
Clin Pathol 2008;129(1):110-14.
Nofech-Mozes S, Holloway C, Hanna W. The role
of cytokeratin 5/6 as an adjunct to diagnostic tool
in breast core needle biopsies. Intl J Surg Pathol
2008;16:399-406.
Ride with Lance
McWhirter E, Yogendran G, Wright FC, Dranitsaris,
Clemons M: Baseline radiologic staging in primary
breast cancer: Impact of education interventions on
adherence to published guidelines. J Eval Clin Pract
2007;13(4):647-50.
Palmer J, Venkateswaran V, Fleshner NE, Klotz LH,
Cox, ME. The impact of diet and micronutrient
supplements on the expression of neuroendocrine
markers in murine Lady transgenic prostate.
Prostate 2008;68(4):345-53.
Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K,
Ciofani M, Caparros E, Buteau J, Brown K, Perkins SL,
Bhagat G, Agarwal AM, Basso G, Castillo M, Nagase
S, Cordon-Cardo C, Parsons R, Zúñiga-Pflücker JC,
Dominguez M, Ferrando AA. Mutational loss of
PTEN induces resistance to NOTCH1 inhibition in
T-cell leukemia. Nat Med 2007;13(10):1203-10
Pang G, Bani-Hashemi A, Au P, O’Brien PF,
Rowlands JA, Morton G, Lim T, Cheung P, Loblaw
A. Megavoltage cone beam digital tomosynthesis
(MV-CBDT) for image-guided radiotherapy: a
clinical investigational system. Phys Med Biol
2008;53(4):999-1013.
Parmigiani G, Chen S, Iversen Jr., ES, Friebel TM,
Finkelstein DM, Anton-Culver H, Ziogas A, Weber
BL, Eisen A, Malone KE, Daling JR, Hsu L, Ostrander
EA, Peterson LE, Schildkraut JM, Isaacs C, Corio C,
Leondaridis L, Tomlinson G, Amos CI, Strong LC,
Berry DA, Weitzel JN, Sand S, Dutson D, Kerber
R, Peshkin BN, Euhus DM. Validity of models for
predicting BRCA1 and BRCA2 mutations. Ann Intern
Med 2007;147(7):441-50.
Paszat L, Sutradhar R, Grunfeld E, Gainford C,
Benk V, Bondy S, Coyle D, Holloway C, Sawka C,
Shumak R, Vallis K, van Walraven C. Outcomes of
surveillance mammography after treatment of
primary breast cancer: a population-based case
series. Breast Cancer Res Treat 2009;114(1):169-78.
Pawlicki T, Yoo S, Court LE, McMillan SK, Rice R.,
Russell JD, Pacyniak JM, Woo MK, Basran PS, Boyer
AL, Bonilla C. Process control analysis of IMRT
QA: Implications for clinical trials. Phys Med Biol
2008;53(18):5193-5205.
Pawlicki T, Yoo S, Court LE, McMillan SK, Rice
RK, Russell JD, Pacyniak JM, Woo MK, Basran
PS, Shoales J, Boyer AL. Moving from IMRT QA
measurements toward independent computer
calculations using control charts. Radiother Oncol
2008;89:330-7.
Perri D, Cole DE, Friedman O, Piliotis E, Mintz S,
Adhikari NK. Azathioprine and diffuse alveolar
haemorrhage: The pharmacogenetics of
thiopurine methyltransferase. Eur Respir J 2007;
30(5):1014-7.
Perry J, Chambers A, Spithoff K, Laperriere N.
Gliadel wafers in the treatment of malignant
glioma: a systematic review. Curr Oncol
2007;14(5):189-94.
Perry J, Laperriere N, Zuraw L, Chambers A, Spithoff
K, Cairncross JG. Adjuvant chemotherapy for adults
with malignant glioma: a systematic review. Can J
Neurol Sci 2007;34(4):402-10.
Pickles T, Morgan S, Morton G, Souhami L, Warde
P, Lukka H. Adjuvant radiotherapy following
radical prostatectomy: Genito-Urinary Radiation
Oncologists of Canada Consensus Statement. Can
Urol Assoc J 2008;2(2):95-9.
Pignol JP, Olivotto I, Rakovitch E, Gardner S, Sixel K,
Beckham W, Vu TT, Truong P, Ackerman I, Paszat L.
A multicenter randomized trial of breast intensitymodulated radiation therapy to reduce acute radiation
dermatitis. J Clin Oncol 2008;26(13):2085-92.
Pichardo, S, Hynynen, K. Circumferential lesion
formation around the pulmonary veins in the left
atrium with focused ultrasound using a 2D-array
endoesophageal device: a numerical study. Phys
Med Biol 2007;52(16):4923-42.
Pisano ED, Hendrick RE, Yaffe MJ, Baum JK,
Acharyya S, Cormack JB, Hanna LA, Conant EF,
Fajardo LL, Bassett LW, D’Orsi CJ, Jong RA, Rebner
M, Tosteson AN, Gatsonis CA; DMIST Investigators
Group. Diagnostic accuracy of digital versus film
mammography: exploratory analysis of selected
population subgroups on DMIST. Radiology
2008;246(2):376-83.
Pisters KM, Evans WK, Azzoli CG, Kris MG, Smith CA,
Desch CE, Somerfield MR, Brouwers MC, Darling
G, Ellis PM, Gaspar LE, Pass HI, Spigel DR, Strawn
JR, Ung YC, Shepherd FA. Cancer Care Ontario and
American Society of Clinical Oncology adjuvant
chemotherapy and adjuvant radiation therapy for
stages I-IIIA resectable non small-cell lung cancer
guideline. J Clin Oncol 2007;25(34):5506-18.
Poon I, Xia P, Weinberg V, Sultanem K, Akazawa
C, Akazawa P, Verhey L, Quivey JM, Lee N. A
treatment planning analysis of inverse-planned
and forward-planned intensity-modulated
radiation therapy in nasopharyngeal carcinoma.
Int J Radiat Oncol Biol Phys 2007;69(5):1625-33.
Pritchard KI, Messersmith H, Elavathil L, Trudeau
M, O’Malley F, Dhesy-Thind B. HER-2 and
topoisomerase II as predictors of response to
chemotherapy. J Clin Oncol 2008;26(5):736-44.
Pritchard KI. Combining endocrine agents
with chemotherapy: Which patients and what
sequence? Cancer 2008;112(3 Suppl):718-22.
Pritchard KI. Adjuvant therapy of the very young
woman. Breast 2007;16 Suppl 2:136-46.
Pritchard KI, Risk of chemotherapy induced
menopause: more detailed data will lead
to improved quality of life. Eur J Cancer
2007;43(11):1644-5.
3 9
C a n c e r
R e s e a r c h
&
I n n o v a t i o n
Publication Highlights
Pritchard KI. Antihormone therapy in recurrent
metastatic breast cancer. JAMA 2008;299(23): 2745.
Pritchard KI. Should observational studies be a thing
of the past? J Natl Cancer Inst 2008;100(7): 451-2.
Pritchard KI. Combining endocrine agents
with chemotherapy: which patients and what
sequence? Cancer 2008;112(3 Suppl):718-22.
Quirt I, Verma S, Petrella T, Bak K, Charette M.
Temozolomide for the treatment of metastatic
melanoma: a systematic review. Oncologist
2007;12(9):1114-23.
Rabeneck L. What can we do about low colorectal
cancer screening rates? Am J Gastroenterol
2007;102:1736-8.
Rabeneck L, Rumble RB, Axler J, Smith A, Armstrong
D, Vinden C, Belliveau P, Rhodes K, Zwaal C, Mai
V, Dixon P. Cancer Care Ontario Colonoscopy
Standards: Standards and evidentiary base. Can J
Gastroenterol 2007;21(Suppl D):5D-24D.
Rakovitch E, Pignol JP, Hanna W, Narod S, Spayne J,
Nofech-Mozes S, Chartier C, Paszat L. Significance of
multifocality in ductal carcinoma in situoutcomes
of women treated with breast-conserving therapy. J
Clin Oncol 2007;25(35):5591-6.
Ramanathan RK, Bjarnason GA, Bernard SA,
Desimone P, Braich T, Evars JP, Hrushesky WJ,
Jolivet J. A four-arm, randomized, multicenter
phase II trial of oxaliplatin combined with varying
schedules of 5-fluorouracil as first-line therapy in
previously untreated advanced colorectal cancer.
Clin Colorectal Cancer 2008;7(2):134-9.
Ravi A, Caldwell CB, Keller BM, Reznik A, Pignol JP.
Online gamma-camera imaging of 103Pd seeds
(OGIPS) for permanent breast seed implantation.
Phys Med Biol 2007;52(19):5921-32.
4 0
R e p o r t
2 0 0 9
A Partial Summary of Full Publications from July 2007 to June 2008
Ravi A, Caldwell CB, Pignol JP. Experimental
evaluation of an online gamma-camera imaging
of permanent seed implantation (OGIPSI)
prototype for partial breast irradiation. Med Phys
2008;35(6):2485-92.
Reznik N, Komljenovic PT, Germann S, Rowlands
JA. Digital radiography using amorphous selenium:
photoconductively activated switch (PAS) readout
system. Med Phys 2008;35(3):1039-50.
Risebrough NA, Verma S, Trudeau M, Mittmann
N. Cost-effectiveness of switching to exemestane
versus continued tamoxifen as adjuvant therapy
for postmenopausal women with primary breast
cancer. Cancer 2007;110(3):499-508.
Rychak JJ, Graba J, Cheung AM, Mystry BS,
Lindner JR, Kerbel RS, Foster FS. Microultrasound
molecular imaging of vascular endothelial growth
factor receptor 2 in a mouse model of tumor
angiogenesis. Mol Imaging 2007;6(5):289-96.
Sahgal A, Chou D, Ames C, Ma L, Lamborn K,
Huang K, Chuang C, Aiken A, Petti P, Weinstein
P, Larson D. Image-guided robotic stereotactic
body radiotherapy for benign spinal tumors:
the University of California San Francisco
preliminary experience. Technol Cancer Res Treat
2007;6(6):595-604.
Sahgal A, Roach M, 3rd. Permanent prostate seed
brachytherapy: a current perspective on the
evolution of the technique and its application. Nat
Clin Practice Urol 2007;4(12):658-70.
Sassaroli E, Hynynen K. Cavitation threshold
of microbubbles in gel tunnels by
focused ultrasound. Ultrasound Med Biol
2007;33(10):1651-60.
Schiller DE, Cummings BJ, Rai S, Le LW, Last
L, Davey P, Easson A, Smith AJ, Swallow CJ.
Outcomes of salvage surgery for squamous cell
carcinoma of the anal canal. Ann Surg Oncol
2007;14(10):2780-9.
Schultz SE, Vinden C, Rabeneck L. Colonoscopy and
flexible sigmoidoscopy practice patterns in Ontario:
A population-based study. Can J Gastroenterol
2007;21:431-4.
Snyder CF, Earle CC, Herbert RJ, Neville BA,
Blackford AL, Frick KD. Preventive care for
colorectal cancer survivors: a 5-year longitudinal
study. J Clin Oncol 2008;26(7):1073-9.
Snyder, CF, Earle CC, Herbert RJ, Neville BA,
Blackford AL, Frick KD. Trends in follow-up and
preventive care for colorectal cancer survivors. J
Gen Intern Med 2008;23(3):254-9.
Soon Wong N, Seong Ooi W, Pritchard KI. Role of
gonadotropin-releasing hormone analog in the
management of male metastatic breast cancer is
uncertain. J Clin Oncol 2007;25(24):3787.
Spaner DE, Foley R, Galipeau J, Bramson J.
Obstacles to effective Toll-like receptor agonist
therapy for hematologic malignancies. Oncogene
2008;27(2):208-17.
Spayne J, Ackerman I, Milosevic M, Seidenfeld A,
Covens A, Paszat L. Invasive cervical cancer: a failure
of screening. Eur J Public Health 2008;18(2):162-5.
Stilos K, Doyle C, Daines P. Addressing the sexual
health needs of patients with gynecologic cancer.
Clin J Oncol Nurs 2008;12(3):457-63.
Stokes ME, Thompson D, Montoya EL, Weinstein
MC, Winer EP, Earle CC. Ten-year survival and cost
following breast cancer recurrence: estimates from
SEER-medicare data. Value Health 2008;11(2):213-20.
Supiot S, Shubbar S, Fleshner N, Warde P,
Hersey K, Wallace K, Cole H, Sweet J, Tsihlias J,
Jewett MA, Klotz L, Bristow RG. A phase I trial of
pre-operative radiotherapy for prostate cancer:
Clinical and translational studies. Radiother Oncol
2008;88(1):53-60.
Szeto TC, Webster CA, Koprinarov I, Rowlands
JA. The x-ray light valve: a potentially low-cost,
digital radiographic imaging system – a liquid
crystal cell design for chest radiography. Med Phys
2008;35(3):959-67.
Ride with Lance
Szumacher E, Catton P, Jones GA, Bradley R,
Kwan J, Cherryman F, Palmer C, Nyhof-Young
J. Helping learners in difficulty--the incidence
and effectiveness of remedial programmes of
the Medical Radiation Sciences Programme at
University of Toronto and the Michener Institute for
Applied Sciences, Toronto, Ontario, Canada. Ann
Acad Med Singapore 2007;36(9):725-34.
Szumacher E, Warner E, Zhang L, Kane G, Ackerman
I, Nyhof-Young J, Agboola O, de Metz C, Rodrigues
G, Voruganti S, Rappolt S. Ontario radiation
oncology residents’ needs in the first postgraduate
year-residents’ perspective survey. Int J Radiat
Oncol Biol Physics 2007;69(2):512-17.
Tan JC, Coburn NG, Baxter NN, Kiss A, Law
CH. Surgical management of intrahepatic
cholangiocarcinoma--a population-based study.
Ann Surg Oncol 2008;15(2):600-8.
Taylor C, Schultz SE, Paszat LF, Bondy S, Rabeneck
L. Prevalence of screening in patients newly
diagnosed with colorectal cancer in Ontario. Can J
Gastroenterol 2007;21(12):805-8.
Traister A, Shi W, Filmus J. Mammalian Notum
induces the release of glypicans and other GPIanchored proteins from the cell surface. Biochem J
2008;410:503-11.
Verma S, Sehdev S, Joy AA. Cancer therapy
disparity: unequal access to breast cancer
therapeutics and drug funding in Canada. Curr
Oncol 2007;(14 Suppl 1):S3-S10.
Trinkaus M, Trudeau M, Callum J. Drug-induced
immune thrombocytopenic purpura secondary to
sunitinib. Curr Oncol 2008;15(3):152-4.
Verma S. Trastuzumab in the adjuvant setting:
concurrent or sequential? It takes two to tango!
Curr Oncol 2008;15(1):66-7.
Ung YC, Maziak DE, Vanderveen JA, Smith
CA, Gulenchyn K, Lacchetti C, Evans WK.
18Fluorodeoxyglucose positron emission
tomography in the diagnosis and staging of lung
cancer: a systematic review. J Natl Cancer Inst
2007;99(23):1753-67.
Verma S, Petrella T, Hamm C, Bak K, Charette M.
Biochemotherapy for the treatment of metastatic
malignant melanoma: a clinical practice guideline.
Curr Oncol 2008;15(2):85-9.
van de Vijver M, Bilous M, Hanna W, Hofmann M,
Kristel P, Penault-Llorca F, Ruschoff J. Chromogenic
in situ hybridisation for the assessment of HER2
status in breast cancer: an international validation
ring study. Breast Cancer Res 2007;9(5):R68.
Van Poppel H, Da Pozzo L, Albrecht W, Matveev
V, Bono A, Borkowski A, Marechal JM, Klotz
L, Skinner E, Keane T, Claessens I, Sylvester
R; European Organization for Research and
Treatment of Cancer (EORTC); National Cancer
Institute of Canada Clinical Trials Group (NCIC
CTG); Southwest Oncology Group (SWOG);
Eastern Cooperative Oncology Group (ECOG). A
prospective randomized EORTC intergroup phase
3 study comparing the complciations of elective
nephron-sparing surgery and radical nephrectomy
for low-stage renal cell carcinoma. Eur Urol
2007;51:1606-15.
Tilanus-Linthorst MM, Obdeijn IM, Hop WC, Causer
PA, Leach MO, Warner E, Pointon L, Hill K, Klijn
JG, Warren RM, Gilbert FJ. BRCA1 mutation and
young age predict fast breast cancer growth in the
Dutch, United Kingdom, and Canadian magnetic
resonance imaging screening trials. Clin Cancer Res
2007;13(24):7357-62.
Venkateswaran V, Haddad AQ, Fleshner NE, Fan R,
Sugar LM, Nam R, Klotz LH, Pollak M. Association
of diet-induced hyperinsulinemia with accelerated
growth of prostate cancer (LNCaP) xenografts. J
Natl Canc Inst 2007;23:1793-800.
Towns K, Bedard PL, Verma S. Matters of the
heart: cardiac toxicity of adjuvant systemic
therapy for early-stage breast cancer. Curr Oncol
2008;15(Suppl1):S16-29.
Verma S, Clemons M. First-line treatment options
for patients with HER-2 negative metastatic
breast cancer: the impact of modern adjuvant
chemotherapy. Oncologist 2007;12(7):785-97.
Warner E. The role of magnetic resonance imaging
in screening women at high risk of breast cancer.
Top Magn Reson Imaging 2008;19(3):163-9.
Warner E, Messersmith H, Causer P, Eisen A,
Shumak R, Plewes D. Systematic review: using
magnetic resonance imaging to screen women
at high risk for breast cancer. Ann Intern Med
2008;148(9):671-9.
Webster CA, Koprinarov I, Germann S, Rowlands
JA. The x-ray light valve: a potentially low-cost,
digital radiographic imaging system-concept
and implementation considerations. Med Phys
2008;35(3):939-49.
Yang W, Lam P, Kitching R, Kahn HJ, Yee A, Aubin
JE, Seth A. Breast cancer metastasis in a human
bone NOD/SCID mouse model. Cancer Biol Ther
2007;6(8):1289-94.
Yee AJ, Akens M, Yang BL, Finkelstein J, Zheng PS,
Deng Z, Yang B. The effects of versican G3 domain
on local breast cancer invasiveness and bony
metastasis. Breast Cancer Res 2007;9(4):R47.
Zhang S, Phelan CM, Zhang P, Rousseau F,
Ghadirian P, Robidoux A, Foulkes W, Hamel N,
McCready D, Trudeau M, Lynch H, Horsman D,
De Matsuda ML, Aziz Z, Gomes M, Costa MM,
Liede, A, Poll P, Sun P, Narod SA. Frequency of the
CHEK2 1100delC mutation among women with
breast cancer: an international study. Cancer Res
2008;68(7):2154-7.
4 1
Rankings
Of Comprehensive Cancer Centres In North America
..................................................................................................................
1
2
3
4
MD Anderson (Houston)
Memorial Sloan-Kettering (New York)
H. Lee Moffitt (Tampa)
Dana-Farber (Boston)
5 Princess Margaret Hospital (Toronto)
6 Odette Cancer Centre, Sunnybrook (Toronto)
Others
Ranking according to number of new patients seen in 2006/07.
..................................................................................................................
5 6
2
1
3
4
ODETTE CANCER CENTRE
2 0 7 5 B a y v i e w Av e n u e
To ro n t o , O N , C a n a d a , M 4 N 3 M 5
Te l e p h o n e : 4 1 6 . 4 8 0 . 6 1 0 0
w w w. s u n n y b ro o k . c a / p ro g r a m s / o c c